Our recent work suggests that assessing C-X-C motif chemokine ligand 12 (CXCL12) levels in CSF could serve as a valuable complementary diagnostic biomarker for amyotrophic lateral sclerosis, but not as a prognostic biomarker.18 In the context of other neurological conditions, our findings revealed a significant increase in CXCL12 levels in the CSF of MS patients but remained unaltered in other neurodegenerative conditions as assessed in our comparative study.18 This data in MS indicated that is not a specific marker for amyotrophic lateral sclerosis. Here, CXCL12 is linked to myeloid sarcoma.